Literature DB >> 15897376

Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study.

Christina Y Chia1, Whitney Lane, John Chibnall, Angel Allen, Elaine Siegfried.   

Abstract

OBJECTIVE: To determine whether patients with moderate to severe acne who were treated with isotretinoin experienced significant increases in depressive symptoms over a 3- to 4-month period compared with patients who received conservative acne therapy.
DESIGN: Cohort study.
SETTING: Hospital-affiliated and community-based clinics in St Louis, Mo. PARTICIPANTS: One hundred thirty-two subjects aged 12 to 19 years with moderate to severe acne. MAIN OUTCOME MEASURES: Depressive symptoms were assessed using the Center for Epidemiological Studies Depression Scale (CES-D), a standardized self-reported instrument. Mean CES-D scores were compared between treatment groups, as were the prevalence and incidence of scores suggestive of clinically significant depression (CES-D score >16).
RESULTS: A total of 101 subjects completed the study. At follow-up, CES-D scores (adjusted for baseline CES-D score and sex of patient) suggestive of clinically significant depression were no more prevalent in the isotretinoin group than in the conservative therapy group. Similarly, the incidence (new onset) of depressive symptoms suggestive of clinical significance also was not significantly different between the treatment groups.
CONCLUSIONS: The use of isotretinoin in the treatment of moderate-severe acne in adolescents did not increase symptoms of depression. On the contrary, treatment of acne either with conservative therapy or with isotretinoin was associated with a decrease in depressive symptoms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897376     DOI: 10.1001/archderm.141.5.557

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  22 in total

1.  Effective monitoring of isotretinoin safety in a pediatric dermatology population: a novel "patient symptom survey" approach.

Authors:  Chelsea J Hodgkiss-Harlow; Lawrence F Eichenfield; Magdalene A Dohil
Journal:  J Am Acad Dermatol       Date:  2011-05-31       Impact factor: 11.527

Review 2.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

3.  The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions.

Authors:  James J Leyden; James Q Del Rosso; Eric W Baum
Journal:  J Clin Aesthet Dermatol       Date:  2014-02

4.  Isotretinoin was not associated with depression or anxiety: A twelve-week study.

Authors:  Bella Suarez; Ana Serrano; Yves Cova; Trino Baptista
Journal:  World J Psychiatry       Date:  2016-03-22

Review 5.  Retinoic acid and affective disorders: the evidence for an association.

Authors:  J Douglas Bremner; Kirsty D Shearer; Peter J McCaffery
Journal:  J Clin Psychiatry       Date:  2011-08-23       Impact factor: 4.384

Review 6.  Inter-relationships between isotretinoin treatment and psychiatric disorders: Depression, bipolar disorder, anxiety, psychosis and suicide risks.

Authors:  Maude Ludot; Stephane Mouchabac; Florian Ferreri
Journal:  World J Psychiatry       Date:  2015-06-22

7.  Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study.

Authors:  Anders Sundström; Lars Alfredsson; Gunilla Sjölin-Forsberg; Barbro Gerdén; Ulf Bergman; Jussi Jokinen
Journal:  BMJ       Date:  2010-11-11

Review 8.  Acne vulgaris.

Authors:  Sarah Purdy; David Deberker
Journal:  BMJ Clin Evid       Date:  2008-05-15

Review 9.  The neurobiology of retinoic acid in affective disorders.

Authors:  J Douglas Bremner; Peter McCaffery
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-07-10       Impact factor: 5.067

10.  Isotretinoin and psychopathology: a review.

Authors:  Vassilis P Kontaxakis; Demetris Skourides; Panayotis Ferentinos; Beata J Havaki-Kontaxaki; George N Papadimitriou
Journal:  Ann Gen Psychiatry       Date:  2009-01-20       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.